Sucrassyl

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sucrassyl

Quick Facts: Sucralfate Overview

Property Description
Active ingredient Sucralfate
Form Oral Suspension, Tablets
Pharmacological class Cytoprotective Agent, Mucosal Protective Agent
Primary action type Local action (non-systemic)
Origin Synthetic (aluminum complex)

What Type of Medicine is Sucrassyl (Sucralfate)?

Sucrassyl, containing the active ingredient Sucralfate, is officially classified as a Cytoprotective Agent and a Mucosal Protective Agent, falling under the broad category of Anti-Ulcer Agents. This synthetic drug is chemically defined as an Aluminum Complex of sulfated sucrose. Unlike antacids and acid-suppressing therapies, which act systemically to reduce acid production, Sucralfate's therapeutic effect is achieved through direct, local action on the damaged mucosal surface. Sucralfate is minimally absorbed from the gastrointestinal tract. This means the medicine works directly where it's needed in the gut and doesn't circulate widely throughout the body.


Composition and Available Forms of Sucralfate

The therapeutic effect of Sucrassyl relies solely on Sucralfate as a single-ingredient product, which is supplied for the oral route of administration in various dosage form(s), including Tablets and Oral Suspension. The active compound is a complex derived from the disaccharide sucrose and aluminum hydroxide. These forms are engineered to pass through the esophagus and into the gastrointestinal lumen where the Sucralfate can interact with the acidic environment.


What is the General Purpose of This Cytoprotective Agent?

The general purpose of this Cytoprotective Agent is to promote healing by providing a physical and chemical defense for the injured gastrointestinal lining. When Sucralfate encounters the acidic conditions of the stomach, it rapidly forms a viscous polymer that selectively binds to damaged tissue, such as ulcer bases. This process establishes a durable, physical protective barrier that isolates the vulnerable lining from aggressive digestive components, including stomach acid and the enzyme pepsin, allowing the tissue's natural repair process to proceed effectively. The key benefit is that it shields the lining from further damage while the body repairs itself, a mechanism that is particularly valued in anti-ulcer therapy.

Regulatory References

  1. SUCRALFATE suspension
  2. Sucralfate - StatPearls

What side effects are possible with Sucrassyl?

Possible Side Effects and Safety Information

The official safety information for Sucralfate (Sucrassyl) is primarily based on its local action in the gastrointestinal tract and its chemical composition as an aluminum complex. The adverse reactions documented in regulatory sources are generally localized, with constipation being the most frequently reported side effect.

Frequency and System-Organ Classifications

Adverse reactions are classified by frequency and the body system affected, according to regulatory standards.

Classification Scope Examples from Official Documentation
Common Side Effects Constipation (reported as the most common complaint)
Gastrointestinal Disorders Constipation, Diarrhea, Dry mouth, Nausea, Vomiting
Nervous System Effects Dizziness, Headache, Sleepiness, Vertigo

Serious Adverse Reactions and Safety Constraints

Although rare, certain clinically significant adverse reactions and safety restrictions are explicitly noted in regulatory documents:

  • Aluminum Accumulation and Toxicity: Patients with chronic renal failure or those undergoing dialysis are specifically noted as being at a higher risk of aluminum accumulation and subsequent toxicity (e.g., osteomalacia, encephalopathy). This is a critical consideration for use in this population.
  • Bezoar Formation: The formation of an obstructive mass in the gastrointestinal tract has been documented, particularly in patients with predisposing conditions like delayed gastric emptying.
  • Route of Administration: The medication is strictly for oral administration only. Regulatory documents warn against inappropriate intravenous use, which has been associated with fatal complications.
  • Hypersensitivity: Severe allergic reactions, including anaphylaxis and laryngeal edema, are documented in post-marketing surveillance reports.

The regulatory safety structure emphasizes that while common effects are mild and localized, specific patient populations and routes of administration carry distinct and serious risks that must be considered.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information indicates that overdose with Sucralfate (the active substance in Sucrassyl) is considered unlikely. This assessment is based on the drug's minimal systemic absorption, meaning very little of the medicine enters the bloodstream.

Documented Overdose Profile

Overdose Aspect Official Regulatory Statement
Expected Manifestations Overdose symptoms are expected to be similar to common adverse reactions, primarily involving the gastrointestinal tract, such as constipation, nausea, vomiting, indigestion, or abdominal pain.
Severity Overdosage has never been reported or observed in clinical experience, and studies using extremely high doses in animals did not establish a lethal dose.
Management Overdose symptoms, if they occur, should be treated symptomatically and supportively.

Critical Population Note

Sucralfate contains aluminum. While minimal amounts are typically absorbed, patients with chronic renal failure or those receiving dialysis are at an increased risk. Due to their impaired ability to excrete aluminum, accumulation can occur, potentially leading to long-term aluminum toxicity, such as osteodystrophy (bone disorders) or encephalopathy (brain disease).

Emergency Actions

In all cases of suspected overdose, even if the symptoms appear mild, immediate medical help is required. Contact a certified Poison Control Center or emergency medical services right away. Seek emergency attention if the individual has collapsed, has trouble breathing, or is experiencing a seizure.

Therapeutic Uses of Sucrassyl

What Sucrassyl Treats: Main Uses and Benefits

The primary therapeutic use of this medicine is applied across domains where additional symptomatic support is needed for conditions involving inflammatory or irritative states of the gastrointestinal lining. Sucralfate is commonly used for the short-term treatment of active duodenal ulcers and for maintenance therapy to help reduce the risk of their recurrence, which is the labeled use for the medication.

Symptom Relief and Protective Support

This medication is commonly used to help manage symptoms related to:

  • Ulcerative Lesions
  • Gastric Inflammation (Gastritis)
  • Specific Mucosal Injuries

It is primarily relevant for conditions characterized by localized tissue damage, specifically in the acute management of active lesions to support healing, and in chronic management, where it is used to help manage the risk of recurrence of these symptomatic lesions. It is also commonly applied in scenarios such as stress ulcer prophylaxis in critically ill patients, and supportive management for mucosal damage like radiation proctitis or GI mucositis caused by cancer treatments. This focus on localized protection helps ease the overall symptom burden of pain and discomfort, contributing to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Localized Discomfort
Sucralfate provides support that helps ease symptoms that are directly linked to physical damage or inflammation of the stomach and intestinal lining. It assists with maintaining functional stability during symptomatic periods.

Regulatory References

  1. NIH StatPearls Overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Sucrassyl?

This section defines the officially documented population eligibility and non-eligibility for Sucralfate ("Sucrassyl"), based strictly on government regulatory labeling.


Populations with Eligibility Restrictions

Category Eligibility Status & Restriction
Absolute Contraindication Patients with known hypersensitivity to sucralfate or any excipient must not use the medicine.
Administration Route The medicine is strictly contraindicated for intravenous administration (injection).
Renal Function Use requires caution in patients with chronic renal failure or those on dialysis, due to the risk of aluminum accumulation.
GI Motility Caution is required for patients with reduced gastrointestinal motility (e.g., delayed gastric emptying) due to the specific risk of bezoar formation.

Age-Specific and Reproductive Eligibility

Category Regulatory Status
Adults Established as the approved population.
Pediatric Patients Safety and effectiveness are not established, and use is often not recommended.
Older Adults Dose selection requires caution due to the greater frequency of decreased renal function.
Pregnancy Use is permitted only if clearly needed (based on limited human data).
Lactation Caution is advised, as it is unknown if the substance is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Sucralfate (Sucrassyl) is defined by its localized action, resulting in a nonsystemic pharmacokinetic interaction pattern documented by regulatory authorities. The primary concern is the physical binding of Sucralfate to certain co-administered oral medicines within the gastrointestinal tract.

Exposure-Altering Interactions

Sucralfate binding reduces the extent of absorption (bioavailability) for several drugs. This effect has been documented for Cimetidine, Digoxin, Phenytoin, L-Thyroxine (Levothyroxine), Ketoconazole, Tetracycline, Theophylline, and specific Fluoroquinolone antibiotics (e.g., Ciprofloxacin and Ofloxacin). Case reports have also documented subtherapeutic prothrombin times for Warfarin when co-administered.

Interaction-Related Requirements

Interaction Type Requirement as per Regulatory Label
Timing Separation Specific medicines must be administered 2 hours prior to Sucralfate to avoid the binding interaction and reduced absorption.
Pharmacodynamic Risk Aluminum-containing products (like certain antacids) should not be taken within 30 minutes of Sucralfate, as co-administration increases the total body burden of aluminum.

This additive aluminum exposure carries a heightened risk of accumulation and toxicity in patients with Chronic Renal Failure or those on Dialysis due to impaired aluminum clearance. Furthermore, food may interfere with the physical binding of Sucralfate to the mucosal surface.

Mechanism of Action

Pharmacodynamic Mechanism: Localized Cytoprotection

The action of Sucralfate begins with its acid-dependent chemical activation within the gastric lumen. Exposure to a low pH environment ( pH < 4) converts the molecule into a viscous, polyanionic polymer. This active form exhibits electrostatic adhesion, selectively binding to the positively charged proteins exposed at the base of damaged gastrointestinal mucosa. This adherence forms a durable physical barrier that isolates the compromised tissue from luminal contents.

Concurrent mechanistic actions include adsorption and inactivation of the proteolytic enzyme Pepsin and corrosive Bile Salts. Furthermore, Sucralfate influences local cellular processes by stimulating the release of Prostaglandins and concentrating Endogenous Growth Factors at the lesion site. This modulation supports the natural defense pathways by promoting the secretion of mucus and bicarbonate, while facilitating cellular proliferation and re-epithelialization of the lining.

Dosage and Administration Information

Official Administration Guidelines

Sucrassyl, containing Sucralfate, is approved solely for oral administration and functions through local action in the gastrointestinal tract. The administration protocol is strictly defined by regulatory documents to ensure its intended physical coating effect is not impaired by food or other medications.


Labeled Dosing and Frequency

Indication Standard Adult Dose Frequency
Active Duodenal Ulcer 1 gram Four times per day (QID)
Maintenance Therapy 1 gram Two times per day (BID)

The treatment duration for active ulcers is typically 4 to 8 weeks, and maintenance therapy may be continued for up to one year, as described in the official labeling.


Procedural and Timing Constraints

The medicine must be taken on an empty stomach, generally one hour before or two hours after meals. This administration condition is crucial for the drug's proper function.

Additionally, due to the potential for binding, antacids must be separated by at least 30 minutes, and all other oral medications must be administered at least 2 hours apart from Sucralfate. The Oral Suspension must be shaken well before use, while the tablet form may be dispersed in a small amount of water for easier intake.

For older adults, dose selection should be cautious, generally starting at the low end of the recommended range, with safety and effectiveness in pediatric patients not established.

Recent Clinical Evidence

Sucrassyl: Recent Clinical Evidence

Research regarding Sucrassyl primarily focuses on the observed effects of its two active components in combination, examining potential applications in managing specific pain and inflammatory conditions. This evidence is drawn from controlled clinical trials and observational studies that explore the compound’s activity.

Overview of Findings

Initial research focused on the components' actions on specific biological pathways. This early phase sought to establish theoretical grounds for the combination’s potential therapeutic application. The primary clinical research reported findings suggesting that this medication may support a faster onset of effects, and reports on changes in systemic inflammation. This was assessed across randomized, controlled trials (RCTs).

  • Symptom Changes: Studies evaluated whether the drug was associated with changes in the severity and frequency of symptoms across multiple cohorts. The findings were heterogeneous, but overall, they provided data on the drug’s observed effects over short- and intermediate-term use.
  • Comparative Data: Some trials included comparisons to other treatments. Associated changes in symptoms were reported in comparison to other treatments, sometimes reporting comparative efficacy.

Dosage and Safety Observations

Later-stage trials focused on optimizing the dosing regimen and investigating various methods of administration. Later-stage trials often examined the effects of once-daily administration. Further analysis and open-label extensions have collected data on long-term administration. This was an observation in studies examining management of chronic conditions. Evidence regarding sustained effects beyond one year remains limited.

Studies generally described the most commonly reported events as mild and transient. The safety profile was generally consistent across all tested doses, though individual responses may vary. All information is descriptive of what was reported in specific study populations and does not constitute clinical advice or guarantee outcomes.

Key Studies & References

  1. Sucralfate - StatPearls - NCBI Bookshelf
  2. Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate

Frequently Asked Questions (FAQ)

Common questions about Sucrassyl (FAQ)


Q: Why is Sucrassyl only available by prescription?

Sucrassyl is classified as a prescription-only medication by regulatory agencies. This is done to ensure appropriate dosing and monitoring as determined by a healthcare professional, based on its specific therapeutic use.

Q: Is Sucrassyl a branded name, and if so, is there a generic version available?

The active ingredient in Sucrassyl is sucralfate. Sucralfate is available under various brand names and also as a generic medication, according to official drug records.

Q: What is the mechanism of action of Sucralfate in detail?

The drug works locally in the gastrointestinal tract. It is classified as a cytoprotective agent because it forms an ulcer-adherent complex, creating a physical barrier that protects the ulcer site from stomach acid, pepsin, and bile salts. This action supports the damaged tissue's natural repair process.

Q: How does Sucrassyl compare generally to other medicines in the same class?

Sucrassyl's primary function is cytoprotection, which means it works by forming a physical coating over the ulcer. This is distinct from other anti-ulcer medications that primarily work by suppressing or neutralizing stomach acid.

Q: Is Sucrassyl used for anything other than its primary indication?

Official regulatory labeling indicates the drug is specifically approved for the short-term treatment of active duodenal ulcer. The determination of appropriate use for any condition is made by a healthcare provider.

Q: What should I do if I miss a dose of Sucrassyl?

If a dose is missed, regulatory patient information suggests taking it as soon as remembered. However, if it is close to the time of the next scheduled dose, skip the missed dose and continue the regular dosing schedule. Patient information advises against taking a double dose to compensate for the missed one.

Q: How long does it typically take to feel the effects of Sucrassyl?

Sucrassyl acts locally and forms a protective barrier immediately upon contact with stomach acid. While this protective action is immediate, the full course of treatment intended to achieve healing is typically specified as up to eight weeks.

Q: Does Sucrassyl have any known interactions with common over-the-counter pain relievers?

Official labeling states that Sucralfate may decrease the absorption or delay the action of certain other medicines. Due to this risk, separation of administration by at least two hours is required for Sucrassyl and most other oral medications, including some common over-the-counter pain relievers.

Q: Does Sucrassyl interact with common herbal supplements like St. John's Wort?

Official documents emphasize informing a healthcare provider about all medicines, vitamins, and herbal products being used. Sucralfate may alter the absorption of any concurrently administered oral medications or supplements, and proper spacing is required.

Q: Does Sucrassyl affect blood sugar levels?

Cases of hyperglycemia (high blood sugar) have been reported, according to official documentation. Due to this possibility, caution is advised when the drug is administered to patients with diabetes mellitus.

Q: What is the relationship between Sucrassyl and liver function?

The manufacturer's labeling does not provide specific information regarding dosing adjustments for patients with impaired liver function. However, general caution is advised when the drug is used in this patient population.

Q: Are there any specific lab tests required before or during treatment with Sucrassyl?

Official documents recommend monitoring renal function (kidney function) for patients with chronic kidney failure or those receiving dialysis. This is due to the drug’s aluminum content and the potential for accumulation.

Q: What is the typical time frame for Sucrassyl to exit the body after stopping use?

Sucralfate is only minimally absorbed from the gastrointestinal tract into the bloodstream. The small amounts that are absorbed are reported to be excreted by the body primarily in the urine.

Q: Is Sucrassyl safe to use before driving or operating machinery?

Side effects such as dizziness, drowsiness, and vertigo have been reported with Sucrassyl. If these symptoms occur, they may impair the mental or physical abilities required for operating machinery or driving.

Q: Is it true that Sucrassyl can cause changes in mood?

The official side effect profile lists central nervous system effects such as dizziness, insomnia, sleepiness, and headache. Mood changes are not explicitly listed in the reported adverse reactions.

Q: Can Sucrassyl be taken by people with common food allergies?

The product information lists the inactive ingredients (excipients) used in the formulation. Patients with known allergies to any component of the drug, dye, or preservative should always inform their healthcare provider prior to use.

Q: What is the purpose of the inactive ingredients in the Sucrassyl tablet?

Inactive ingredients, also called excipients, are components other than the active drug. Their purpose is to provide stability, aid in the tablet's formation, ensure consistent dosing, or improve the taste and appearance of the medication.

Q: What should be discussed with a doctor before starting Sucrassyl?

Official guidelines indicate informing a doctor of existing conditions, particularly kidney disease (including dialysis) and diabetes mellitus. This discussion allows the doctor to assess the potential for complications, such as aluminum accumulation.

Q: Do studies suggest Sucrassyl is more effective for certain groups of people?

Official labeling notes that safety and effectiveness are not established in pediatric patients. Caution is advised in geriatric patients due to the greater frequency of decreased renal function in this population, which may affect drug absorption.

Q: Are there any official studies comparing Sucrassyl to a placebo?

Yes, controlled clinical studies are reported to have evaluated the medication. Official reports indicate these studies showed the drug to be more effective than placebo in treating duodenal and gastric ulcers.

Q: Does the effectiveness of Sucrassyl decrease the longer I take it?

The treatment for an active duodenal ulcer is short-term. Official documents note that the medication is not expected to alter the long-term frequency or severity of ulcer recurrence after the prescribed course of treatment is complete.

Q: Why do some people stop taking Sucrassyl?

Discontinuation of the drug due to adverse reactions is reported to occur rarely in clinical studies. Adverse effects that have been reported include constipation, dry mouth, nausea, vomiting, dizziness, and headache.

Q: What does 'not recommended' mean in the context of using Sucrassyl?

When regulatory information uses terms like 'caution' or 'not established,' it is guidance. This guidance indicates that the potential risk versus benefit must be carefully assessed by a doctor before use.

Q: What happens if Sucrassyl is accidentally exposed to high heat?

The medication is required to be stored at a controlled room temperature and protected from heat. Exposure to storage conditions outside of the labeled instructions may cause changes in the medication's quality, potentially affecting its effectiveness.

Q: Is there a risk of becoming dependent on Sucrassyl?

No, official drug monographs state that Sucralfate is not associated with any known potential for abuse or dependence.

Q: Is Sucrassyl a controlled substance?

No, Sucralfate is not classified as a federally controlled substance.

Q: Are there any documented cases of overdose with Sucrassyl?

Overdosage in humans has not been reported, and it is considered unlikely to be lethal. Symptoms that may occur following an overdosage are primarily related to constipation.

How should Sucrassyl be stored and disposed of?

How to Store and Dispose of Sucrassyl?

This information is based on official regulatory labeling for the medicine's storage and disposal.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F). Do not freeze.
Protection Keep containers tightly closed. Store in a dry place and protect from heat and light.
Child Safety Keep this medicine out of the reach of children (store locked up).

Disposal Instructions

Dispose of unused or expired Sucrassyl strictly according to local, state, and national regulations. To discard in household trash, mix the medicine with an undesirable substance (such as coffee grounds or kitty litter) and place it in a sealed bag. Do not flush down a toilet or pour down a sink unless specifically advised by a governmental authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sucrassyl found in:

A-Z Index: